Ocuphire Pharma Investor Day Presentation Deck

RM 49 MIRA-2/3 Phase 3 Registration Trial Design Randomized, Double-Masked, Placebo-Controlled, Parallel, One-Day Trial 12 to 16 US sites 185 to 330 target healthy subjects Eligibility Screening 0.75% Nyxol 1:1 2:1 Placebo Randomization Mydriatic Agent A, B, or C Mydriasis -1 Hour Treatment (Max Dilation) 0 min Mydriatic Agent A, B, or C 1 Hr 30min Nyxol drop(s) (2 drops study eye, 1 drop fellow eye) 2 Hr 3 Hr 90min Placebo drop(s) (2 drops study eye, 1 drop fellow eye) Enrollment MIRA-3 Started in 4Q21 Topline Results Expected in Early 2022 4 Hr Follow Up Visit 6 Hr 24 Hr Mydriatic Agents 3:1:1 - 2.5% phenylephrine (alpha-1 agonist), 1% tropicamide (cholinergic blocker), Paremyd® (combination) Endpoints Primary: % of subjects (study eye) returning to baseline (within 0.2 mm) photopic pupil diameter (PD) at 90 min Secondary: ● ● ● ● ● % of subjects returning to baseline at Omin, 30min, 1h, 90 min 2h, 3h, 4h, 6h, 24h (overall, by mydriatic agent, by iris color) Mean change in pupil diameter at all timepoints Accommodation (Tropicamide/Paremyd) Visual acuity & discomfort w/ glare Pupillary light reflex Safety and tolerability (redness) Ocuphire PHARMA

View entire presentation